Spinraza, the first treatment for the fatal genetic disease spinal muscular atrophy, offered hope that the same technology could transform other devastating neurological diseases. So far, progress has been slow
Antisense technology changed one devastating disease. Why hasn't it transformed others?
The 2016 meeting of the Oligonucleotide Therapeutics Society in Montreal began with a rare mix of promise and elation.
That year, the 27-year-old biotech Ionis …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
